System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Maria Mazurkiewicz-Bełdzińska is an expert in Neurology at University Clinical Centre (Poland). As of October 2026, ScienceLeadR ranks Maria Mazurkiewicz-Bełdzińska in the top 1% of experts in Poland for Epilepsy. Maria Mazurkiewicz-Bełdzińska has authored 188 publications, the most recent in 2026, and is an investigator in 29 clinical trials, 14 of them ongoing. SLR score: 1,065 (community average: 125). How the SLR is computed.

LeadR Profile

Maria Mazurkiewicz-Bełdzińska University Clinical Centre Poland
1 065 ScienceLeadR Reputation 1065

Unlock

Register Login
Network Map

Neurology

Subspecialties: Pediatrics - Genetics - Neurosurgery

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2002 - 2026
Source: PubMed

Gdańsk Medical University

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 188

Citations

Citations: 3 880 1st author: 22 Last author: 76 Unique author: 0

Main journals

Neurology 12
Eur J Paediatr Neurol 11
Polski Przegląd Neurologiczny 9
Neurol Neurochir Pol 8
Ortop Traumatol Rehabil 8

Best Journals

N Engl J Med 4
Lancet Neurol 3
Circulation 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Elevated serum IL-18 and IL-37 levels and their association with seizure burden in paediatric epilepsy.
PMID 42676435 — cytokines, genes, epilepsy, serum, biomarkers, immune system diseases, polymorphism, genetic, seizures, interleukin-18, child		Front Immunol20260
Age-Dependent Progression of Neurological Involvement in PRPP Deficiency: Insights from a Four-Generation Family and Systematic Review.
PMID 42650830 — genes, hearing loss, sensorineural		Biomolecules20260
Early sodium channel blocker initiation is associated with better outcomes in KCNQ2 disorders.
PMID 42610455 — epilepsy, channelopathies, seizures, precision medicine, sodium channel blockers, therapeutics, neurology, sodium channels, neurodevelopment		Brain20261
Enhancing epilepsy and seizure first aid awareness in polish youth: The impact of targeted educational programs.
PMID 42566809 — epilepsy, insemination, artificial, heterologous, seizures, education, first aid		Eur J Paediatr Neurol20260
Caregiver preferences and training needs in the administration of rescue medication for prolonged convulsive seizures in children and adolescents with epilepsy: Results from a multinational survey.
PMID 42462388 — epilepsy, diazepam, caregivers, midazolam, adolescent, seizures, child		Epilepsy Behav20260

Clinical Studies 29

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 3 12
Phase 2 8
Phase 2/Phase 3 5
Phase 4 2
N/A 1
Phase 1/Phase 2 1

By status:

Completed 11
Recruiting 10
Active not recruiting 5
Not yet recruiting 1
Terminated 1
Unknown 1

By type:

Interventional 28
Observational 1

By Monocentric/Multicentric:

monocentric 1
multicentric2to4 4
multicentric5to9 4
multicentricup10 20

Main Topics

Ongoing Clinical Trials

14 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison with Fingolimod in Children and Adolescents with Relapsing Remitting Multiple Sclerosis
2023-506516-40-00 — sclerosis, multiple sclerosis, safety, adolescent, multiple sclerosis, relapsing-remitting, child		Phase 3Active not recruiting2022
A Phase 3 Randomized Double Blind Placebo Controlled Global Study with an Open Label Extension to Evaluate the Efficacy and Safety of Intravenous AOC 1044 (delpacibart zotadirsen) for the Treatment of DMD with Gene Mutations Amenable to Exon 44 Skipping
2025-523087-20-00 — genes, muscular dystrophies, safety, muscular dystrophy, duchenne, exons, therapeutics, mutation		Phase 3Not yet recruiting2026
Efficacy and Safety Study of Once Daily Extended Release Levetiracetam in Drug resistant Focal Onset Seizures
2024-514499-42-00 — epilepsy, safety, pharmaceutical preparations, levetiracetam, seizures, therapeutics		Phase 3Recruiting2025
Ublituximab in Pediatric Participants with Relapsing forms of Multiple Sclerosis (RMS)
2025-522257-19-00 — sclerosis, multiple sclerosis		Phase 2/Phase 3Recruiting2026
A study to learn if fenfluramine hydrochloride is safe and works in people with Rett syndrome
2025-523157-34-00 — safety, fenfluramine, rett syndrome		Phase 3Recruiting2026

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS